Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal
ConditionHemorrhagic Brain Metastases
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorCentre Francois Baclesse
About this trial
This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of FSRT for the management of hemorrhagic brain metastases
Eligibility criteria
Qualifiers
Age> 18 years
Performance Status 0 or 1
Patient with less than 4 brain metastases [of a solid tumor, including melanoma, with a histologically proven diagnosis for the solid tumor; Patients who have had a metastasectomy and 1 to 3 brain metastatic lesions are eligible.
Brain injury (s) measuring between 5 and 30 mm in diameter
Disqualifiers
Patient with small cell lung cancer, germ cell tumors, lymphoma, leukemia and multiple myeloma
Patient with a concomitant neurodegenerative disease
Any symptoms not attributable to cerebral metastasis or cancerous pathology and requiring long-term use of corticosteroids (regardless of dose)
Contraindication to brain MRI or gadolinium injection
Trial design
Treatments tested in this trial
- FSRT Stereotactic radiation therapy
Treatment groups
46 Participants
are divided into 1 treatment groupSponsors and collaborators
Centre Francois Baclesse
Lead sponsor
ANOCEF/IGCNO
Collaborator
Groupement Interrégional de Recherche Clinique et d'Innovation
Collaborator
Source ClinicalTrials.gov